CIK 0000939767
- Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043257395
- Phone
- +1 650-837-7000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-05 | Hessekiel Jeffrey EVP, General Counsel & Sec | Option exercise 10b5-1 | +13,930 | $14.74 | $205K | 621,365 |
| 2023-04-05 | Hessekiel Jeffrey EVP, General Counsel & Sec | Sale 10b5-1 | −38,930 | $20.01 | $779K | 582,435 |
| 2023-04-05 | Hessekiel Jeffrey EVP, General Counsel & Sec | Option exercise · Option (right to buy) 10b5-1 | −13,930 | 55,710 | ||
| 2023-04-03 | Hessekiel Jeffrey EVP, General Counsel & Sec | Grant or award 10b5-1 | +79,719 | 607,435 | ||
| 2023-04-03 | MORRISSEY MICHAEL President and CEO | Grant or award | +313,185 | 642,318 | ||
| 2023-04-03 | Aftab Dana CSO/EVP Disc & Trans Research | Grant or award | +68,331 | 419,803 | ||
| 2023-04-03 | Senner Christopher J. EVP and CFO | Grant or award | +85,414 | 590,077 | ||
| 2023-04-03 | Goodman Vicki L EVP, Prod Dev & Med Aff &CMO | Grant or award | +82,566 | 307,654 | ||
| 2023-04-03 | Haley Patrick J. EVP, Commercial | Grant or award | +79,719 | 332,577 | ||
| 2023-03-10 | WYSZOMIERSKI JACK L Director | Option exercise | +40,000 | $6.30 | $252K | 332,767 |
| 2023-03-10 | WYSZOMIERSKI JACK L Director | Sale | −15,300 | $16.61 | $254K | 317,467 |
| 2023-03-10 | WYSZOMIERSKI JACK L Director | Option exercise · Option (right to buy) | −40,000 | 0 | ||
| 2023-03-01 | Hessekiel Jeffrey EVP, General Counsel & Sec | Option exercise | +27,860 | $14.74 | $411K | 605,576 |
| 2023-03-01 | Hessekiel Jeffrey EVP, General Counsel & Sec | Sale | −77,860 | $17.13 | $1.3M | 527,716 |
| 2023-03-01 | Hessekiel Jeffrey EVP, General Counsel & Sec | Option exercise · Option (right to buy) | −27,860 | 69,640 | ||
| 2023-02-28 | Aftab Dana CSO/EVP Disc & Trans Research | Option exercise | +82,490 | $14.74 | $1.2M | 433,962 |
| 2023-02-28 | Aftab Dana CSO/EVP Disc & Trans Research | Sale | −82,490 | $17.50 | $1.4M | 351,472 |
| 2023-02-28 | Aftab Dana CSO/EVP Disc & Trans Research | Option exercise · Option (right to buy) | −82,490 | 0 | ||
| 2023-02-27 | Aftab Dana CSO/EVP Disc & Trans Research | Option exercise | +10 | $14.74 | $147 | 351,482 |
| 2023-02-27 | Aftab Dana CSO/EVP Disc & Trans Research | Sale | −10 | $17.50 | $175 | 351,472 |
Page 21 of 29 · 580 trades